Cardiac Dimensions®, a leader in minimally invasive treatments for heart failure and functional mitral regurgitation (FMR), today announced the close of an oversubscribed $53 million Series E financing round led by Ally Bridge Group with significant participation from existing investors. This financing will fund the completion of the EMPOWER Trial U.S. pivotal study and support the continued commercialization of the innovative Carillon Mitral Contour System®. “Cardiac Dimensions is uniquely po...

Caldera Medical, a leader in women's health medical devices, has acquired Ethicon’s Gynecare TVT™ family of products and will transition the products in the coming months. This strategic milestone builds on Caldera Medical’s 23-year commitment to delivering best-in-class therapies that improve the quality of life for women worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320644274/en/Caldera Medical is expanding its commi...

Aviator LLC has granted Aviator Studio (www.aviator.studio) an exclusive, irrevocable global license for its branding and intellectual property, covering gambling services and online game production. Aviator LLC, the owner of the original trademark of the globally popular crash game, has also prevailed in its legal challenges against parties accused of infringement. On February 17, Georgia’s Court of Appeal upheld a lower court ruling that SPRIBE OU had registered Aviator LLC’s trademarks in ...

BWT Alpine Formula One Team announces a first-of-its-kind partnership with viagogo, the world’s leading ticket marketplace, making it easier than ever to buy tickets, no matter where they are in the world. With viagogo’s platform available in 195 countries and 33 languages, more fans will have access to the thrill of Formula One, enabling BWT Alpine Formula One Team to reach new audiences and grow its global fanbase. This press release features multimedia. View the full release here: https://ww...

Hai Robotics Europe BV is proud to announce its official membership in the Asociación Española de Manutención (FEM-AEM), effective February 25, 2025. This milestone reinforces the company's dedication to advancing automation and innovation in the material handling industry across Spain and the EMEA region. With the recent release of HaiPick Climb system, joining FEM-AEM further strengthens the company's commitment to industry collaboration and standardization, ensuring that its latest technolog...

The winners of The smarter E AWARD 2025 will be honored on 6 May at the International Congress Center Messe München. The finalists are the following. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320037540/en/The finalists for The smarter E AWARD 2025 have been announced in the five categories. ©Solar Promotion GmbH Finalists in the Photovoltaics category 7Secondsolar (South Africa) with its AUTOPV planning software solution ...

SES S.A. (“SES” or the “Company”) today issued the following statements in relation to the Company’s upcoming Annual General Meeting (“AGM”), taking place on 3 April 2025: Proposed Additions to SES’s Board of Directors The Company is pleased to propose the addition of two new members, Ellen Lord and John Shaw, to its Board of Directors. Ellen Lord is the former Under Secretary of Defense for Acquisition and Sustainment of the United States Department of Defense and has board experience with...

SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced that it will report its full year 2024 financial results before the U.S. market open on Friday, March 28, 2025. The Company will hold a conference call on Friday, March 28, 2025 at 8:00 am Eastern Time (or Friday, March 28, 2025 at 9:00 pm Japan Time) to discuss the financial results and ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD). The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg COMP360 psilocybin demonstrated a lo...